Pharmacokinetic study of single doses of oral fludarabine phosphate in patients with 'low-grade' non-Hodgkin's lymphoma and B-cell chronic lymphocytic leukemia

Journal of Clinical Oncology

Volumn 17, Issue 5, 1999, Pages 1574-1579

  Foran, James M ^a   Oscier, David ^a   Orchard, Jennifer ^a   Johnson, Stephen A ^a   Tighe, Mary ^a   Cullen, Michael H ^a   De Takats, Philippa G ^a   Kraus, Christian ^a   Klein, Marcus ^a   Lister, T Andrew ^a  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FLUDARABINE PHOSPHATE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; B CELL LEUKEMIA; BIOEQUIVALENCE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG METABOLISM; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LYMPHATIC LEUKEMIA; MALE; NONHODGKIN LYMPHOMA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0032949451     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.1999.17.5.1574     Document Type: Article

References (24)

1. Adkins JC, Peters DH, Markham A: Fludarabine: An update of its pharmacology and use in the treatment of haematological malignancies. Drugs 53:1005-1037, 1997
2. Plunkett W, Gandhi V, Huang P, et al: Fludarabine: Pharmacokinetics, mechanisms of action, and rationales for combination therapies. Semin Oncol 20:2-12, 1993 (suppl 7)
3. Warrell RP, Berman E: Phase I and II study of fludarabine phosphate in leukemia: Therapeutic efficacy with delayed central nervous system toxicity. J Clin Oncol 4:74-79, 1986
4. Cheson BD, Vena DA, Foss FM, et al: Neurotoxicity of purine analogs: A review. J Clin Oncol 12:2216-2228, 1994
5. Keating MJ, Kantarjian H, Talpaz M, et al: Fludarabine: A new agent with major activity against chronic lymphocytic leukemia. Blood 74:19-25, 1989
6. Stansfeld AG, Diebold J, Noel H, et al: Updated Kiel classification for lymphomas. Lancet 1:292-293, 1988 (letter)
7. The Non-Hodgkin's Lymphoma Pathologic Classification Project: National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: Summary and description of a working formulation for clinical usage. Cancer 49:2112-2135, 1982
8. Hochster HS, Kim K, Green MD, et al: Activity of fludarabine in previously-treated non-Hodgkin's low-grade lymphoma: Results of an Eastern Cooperative Oncology Group study. J Clin Oncol 10:28-32, 1992
9. Hiddemann W, Unterhalt M, Pott C, et al: Fludarabine single-agent therapy for relapsed low-grade non-Hodgkin's lymphoma: A phase II study of the German low-grade non-Hodgkin's lymphoma study group. Semin Oncol 20:28-31, 1993 (suppl 7)
10. Whelan JS, Davis CL, Rule S, et al: Fludarabine phosphate for the treatment of low grade lymphoid malignancy. Br J Cancer 64:120-123, 1991
11. Zinzani PL, Lauria F, Rondelli D, et al: Fludarabine: An active agent in the treatment of previously-treated and untreated low-grade non-Hodgkin's lymphoma. Ann Oncol 4:575-578, 1993
12. Solal-Celigny P, Brice P, Brousse N, et al: Phase II trial of fludarabine monophosphate as first-line therapy in patients with advanced follicular lymphoma: A multicenter study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 14:514-519, 1996
13. Chronic lymphocytic leukemia: Recommendations for diagnosis, staging, and response criteria - International Workshop on Chronic Lymphocytic Leukemia. Ann Intern Med 110:236-238, 1989
14. Kemena A, Fernandez M, Baumann J, et al: A sensitive fluorescence assay for quantitation of fludarabine and metabolites in biological fluids. Clin Chim Acta 200:95-106, 1991
15. Kemena A, Keating MJ, Plunkett W: Plasma and cellular bioavailability of oral fludarabine. Proc Am Soc Hematol 78:52a, 1991 (suppl 1) (abstr)
16. O'Rourke TJ, Bums HA, Rodriguez, et al: Phase I pharmacokinetic and bioavailability study of five daily intravenous and oral doses of fludarabine phosphate in patients with advanced cancer. Proc Am Soc Clin Oncol 16:736, 1997 (abstr)
17. Klein M, Ludwig W-D, Fulle HH, et al: 2F-ara-A pharmacokineẗ ics including systemic availability during treatment with fludarabine phosphate given either perorally as an immediate release tablet formulä tion, or intravenously as a solution. Onkologie 20:137a, 1997 (suppl 1) (abstr)
18. Heimann G: Tests for dose linearity and tests for zero slope in crossover studies, in Kitsos CP, Edler L (eds): Contributions to Statistics: Industrial Statistics - Aims and Computational Aspects. Heidelberg, Germany, Physica Verlag, 1997, pp 243-256
19. Hersh MR, Kuhn JG, Phillips JL, et al: Pharmacokinetic study of fludarabine phosphate (NSC 312887). Cancer Chemother Pharmacol 17:277-280, 1986
20. McLaughlin P, Hagemeister FB, Romaguera JE, et al: Fludarabine, mitoxantrone and dexamethasone: An effective new regimen for indolent lymphoma. J Clin Oncol 14:1262-1268, 1996
21. Zinzani PL, Bendandi M, Magagnoli M, et al: Fludarabine-mitoxantrone combination-containing regimen in recurrent low-grade non-Hodgkin's lymphoma. Ann Oncol 8:379-383, 1997
22. Klasa R, Connors J, Gascoyne R, et al: CPF (cyclophosphamide, prednisone, fludarabine) in advanced stage previously untreated low-grade and mantle cell lymphoma. Proc Am Soc Hematol 90:342a, 1997 (suppl 1) (abstr)
23. Hochster H, Oken M, Bennett J, et al: Efficacy of cyclophosphä mide and fludarabine as first line therapy of low-grade non-Hodgkin's lymphoma-ECOG 1491. Proc Am Soc Hematol 84:383a, 1994 (suppl 1) (abstr)
24. Pott C, Unterhalt M, Sandford D, et al: Fludarabine as single agent and in combination with mitoxantrone and dexamethasone in relapsed and refractory low-grade non-Hodgkin's lymphoma. Ann Haematol 68:A2, 1994 (suppl 1) (abstr)